/

INCY

Incyte CorporationClosed

111.36−1.43 −1.27%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delayAfter hours 109.00 −2.12%

Open

113.14

Prev close

112.79

Day range

111.27113.56

52-week range

83.46132.60

Volume

1.48M0.91×

Mkt cap

22.57B

P/E ttm

14.01

Fwd P/E

12.75

EPS ttm

7.95

Div yield

0.00%

Earnings

Oct 29, 2026

From 52w high

−16.02%

Price Chart

Yahoo Finance · delayed

INCYOct 12, 2026O 114.05H 114.05L 111.26C 111.36−1.43 (−1.27%)Vol 1.48M

SMA 50122.45
SMA 200107.26

1Y change +32.89% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INCY Incyte Corporation · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −2.43%
1 month: −8.32%
3 months: −2.51%
6 months: +16.55%
Year to date: +12.75%
1 year: +32.89%

Valuation & ownership

Market cap: 22.57B
Enterprise value: 18.07B
P/E (ttm): 14.01
Forward P/E: 12.75
PEG ratio: 10.82
Price / book: 3.53
Price / sales (ttm): 3.88
EV / EBITDA: 9.31
EPS (ttm): 7.95
EPS (forward): 8.73
Beta (5y monthly): 0.74
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 202.70M
Float: 170.41M
Short % of float: 8.40%
Short ratio (days): 6.50
Held by insiders: 1.85%
Held by institutions: 103.39%
Avg volume (3m): 1.62M
50-day average: 122.45
200-day average: 107.26
52-week change: +32.89%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 29.2
vs 50-day SMA: −9.05%
vs 200-day SMA: +3.82%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 2.87%
Realised vol (20d, ann.): 23.6%
From 52-week high: −16.02%
From 52-week low: +34.46%

Signals (TECH)BREAKDOWN RSI ≤ 30

ANR

Analyst Consensus

24 analysts

Consensus

Buy

2.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

129.13

+15.95% implied

Low 86.00Median 129.00High 157.00

Recommendation trend

Now12 / 15 / 1
1m ago

DES

About Incyte Corporation

Yahoo Finance profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Sector: Healthcare
Industry: Biotechnology
Employees: 2,844
Headquarters: Wilmington, DE, United States

SEAS

Seasonality · INCY

2007–2026 · monthly returns

Strongest month Jul +5.56%Weakest month Feb −2.64%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	1.3	1.2	-7.1	1.2	1.5	17.2	5.4	3.1	-1.5	-8.2			+12.7%
2025	7.4	-0.9	-17.6	3.5	3.8	4.7	10.0	13.0	0.2	10.2	11.7	-5.4	+43.0%
2024	-6.4	-0.7	-2.4	-8.6	11.0	4.9	7.3	0.9	0.7	12.1	0.6	-7.4	+10.0%
2023	6.0	-9.6	-6.1	3.0	-17.3	1.1	2.4	1.3	-10.5	-6.6	0.8	15.6	−21.8%
2022	1.3	-8.1	16.3	-5.6	1.2	0.1	2.3	-9.3	-5.4	11.6	7.2	0.8	+9.4%
2021	3.2	-12.4	3.3	5.1	-1.9	0.4	-8.1	-1.1	-10.1	-2.6	1.1	8.4	−15.6%
2020	-16.3	3.2	-2.9	33.4	4.4	2.0	-5.0	-2.4	-6.9	-3.5	-2.4	2.9	−0.4%
2019	26.7	7.0	-0.3	-10.7	2.4	8.1	-0.0	-3.7	-9.3	13.1	12.2	-7.3	+37.3%
2018	-4.7	-5.7	-2.1	-25.7	10.2	-1.9	-0.7	11.1	-6.5	-6.2	-0.9	-1.0	−32.9%
2017	20.9	9.8	0.4	-7.0	4.1	-2.6	5.9	3.1	-15.0	-3.0	-12.6	-4.3	−5.5%
2016	-34.9	4.2	-1.4	-0.3	16.8	-5.2	12.8	-10.1	16.3	-7.8	17.6	-2.0	−7.5%
2015	9.0	7.7	6.8	6.0	13.4	-5.4	0.1	11.4	-5.0	6.5	-2.8	-5.1	+48.3%
2014	29.4	-1.9	-16.7	-9.3	2.0	13.9	-15.7	13.9	-9.5	36.7	12.7	-3.2	+44.4%
2013	10.7	20.9	5.3	-5.4	0.1	-0.8	6.4	44.8	12.6	2.2	19.5	8.6	+204.8%
2012	17.9	-4.2	13.8	17.4	-6.0	6.5	10.1	-19.9	-9.8	-11.6	10.3	-5.6	+10.7%
2011	-11.0	-7.2	15.9	16.6	-4.1	6.8	-7.9	-7.9	-13.1	-1.4	0.0	9.0	−9.4%
2010	17.2	-0.2	30.7	-3.5	-4.1	-14.1	17.6	-3.9	27.8	4.2	-12.9	14.1	+81.8%
2009	-22.7	-21.2	1.3	0.9	39.4	0.0	58.1	26.7	2.4	-12.7	41.4	9.4	+140.4%
2008	19.2	-17.3	6.1	3.2	-10.5	-21.6	21.7	10.5	-25.2	-45.8	-19.5	13.5	−62.3%
2007	27.2	-13.7	2.8	17.0	-8.0	-15.4	-11.3	9.8	22.4	21.1	-0.9	17.1	+72.1%

INSD

Insider Activity · INCY

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

547.3K shares

Sells, 6 months

191.1K shares

Net shares

+356.2K

Net change in insider shares

+10.50%

Date	Insider	Transaction	Shares	Value
Sep 14, 2026	Cagnoni Pablo JOfficer	Sale at price 120.49 - 120.50 per share.	23.2K	$2.80M
Sep 14, 2026	Cagnoni Pablo JOfficer	Conversion of Exercise of derivative security at price 61.18 - 71.93 per share.	23.2K	$1.54M
Aug 18, 2026	Cagnoni Pablo JOfficer	Sale at price 125.56 per share.	10.8K	$1.36M
Aug 11, 2026	Cagnoni Pablo JOfficer	Sale at price 120.04 per share.	10.8K	$1.30M
Aug 4, 2026	Mayes Patrick AOfficer	Sale at price 123.99 per share.	2.2K	$273.65K
Aug 4, 2026	Cagnoni Pablo JPresident	Sale at price 122.69 per share.	10.6K	$1.31M
Aug 4, 2026	Mayes Patrick AOfficer	Conversion of Exercise of derivative security at price 106.47 per share.	2.2K	$234.98K
Aug 2, 2026	Mayes Patrick AOfficer	Sale at price 119.38 - 122.19 per share.	48K	$5.73M
Aug 2, 2026	Mayes Patrick AOfficer	Conversion of Exercise of derivative security at price 61.18 - 106.47 per share.	45.8K	$3.59M
Jul 30, 2026	Cagnoni Pablo JOfficer	Sale at price 119.70 per share.	15.9K	$1.90M
Jul 15, 2026	Issa Mohamed KhairieOfficer	Stock Award(Grant) at price 0.00 per share.	7.9K	—
Jul 15, 2026	Mayes Patrick AOfficer	Stock Award(Grant) at price 0.00 per share.	5.9K	—
Jul 15, 2026	Basi Ramitpal KOfficer	Stock Award(Grant) at price 0.00 per share.	5K	—
Jul 15, 2026	Gardner David HOfficer	Stock Award(Grant) at price 0.00 per share.	7.4K	—
Jul 15, 2026	Hoffman Richard AGeneral Counsel	Stock Award(Grant) at price 0.00 per share.	7.4K	—
Jul 15, 2026	Meury WilliamChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	26.8K	—
Jul 15, 2026	Tray Thomas ROfficer	Stock Award(Grant) at price 0.00 per share.	2.8K	—
Jul 15, 2026	Stein Steven H.Officer	Stock Award(Grant) at price 0.00 per share.	9.8K	—
Jul 15, 2026	Cagnoni Pablo JPresident	Stock Award(Grant) at price 0.00 per share.	13.4K	—
Jul 15, 2026	Issa Mohamed KhairieOfficer	Sale at price 115.01 per share.	1.1K	$125.71K

CONG

Congress Trades · INCY

House reports since 2025

Members

0 last bought

Buys

~$0

Sells

~$8.0K

Net

−$8.0K

est. bought − sold

Latest

May 15, 25

Rob Bresnahan

Members who traded it

Member	Buys	Sells	Est. net	Last move
Rob Bresnahan PA08		1	−$8.0K	Sold May 15, 25

Bought and sold by quarter (est.)

House members' INCY trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
May 15, 25	Rob Bresnahan PA08	Self	Sell	$1,001 - $15,000	May 31, 25 (16d)	PDF

From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

INCY

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INCY

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Incyte Corporation

Seasonality · INCY

Insider Activity · INCY

Congress Trades · INCY

Members who traded it

Bought and sold by quarter (est.)

Congress Trades · INCY

Members who traded it

Bought and sold by quarter (est.)

Seasonality · INCY

Insider Activity · INCY

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Incyte Corporation

Financial Snapshot

Earnings & Dividends

News